DEVLOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF APREMILAST IN TABLET DOSAGE FORM

Mahesh Balkisan Gaikwad, R.K.Dumbare


Narendra M. Gowekar

Chaudhary Attarsingh Yadav Memorial Education Trust Siddhant College of Pharmacy.412109

Abstract- RP-HPLC for the determination of apremilast tablet dosage form the chromatographic s9999on was carried out UV 1700 detector, utilising C18 column (based on 99.999% ultra high purity silica) 150 mm ×4.6 mm $,5\mu$ m particle size, utilising water methanol, triethylamine, at flow rate 1ml/min within injection vol. 20µl was selected for this study. The sepreation was carried out at a room temperature and the eluentant werw observed by photodiode array detector set a 264nm. The retention time of apremilast obtained was at 3.9 min. thus the propose method for APR was found to be feasible for estimation of APR in pharmaceutical dosage form.

Keyword- HPLC, Mobile phas

I. Introduction- Apremilast used to certain type of arthritis (Psoriatic Arthritis). Apremilast is a class phosphodiester-4 inhibitor used in rheumatic arthritis and psoriatic Arthritis phosphodiestarase inhibitor is a cyclic adenosine monophosphate which is predominantly located in inflammatory cells and by inhibiting PDE-4. It increases of CAMP which further inhibit proinflammatory mediatory including interleukin-2 chemically name of aprentilast is $\{N-\{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl])-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl acetamide and mol. Formula C₂₂H₂₄N₂O₇S and Mol. Wt. 460.5 g/mol.$



II. EXPERIMENTAL STUDY

A. Reagents and chemicals-

Water, methanol, triethylamine were used as solvents to prepare mobile phase. All the chemicals used were HPLC grade (Merck Ltd. Mumbai) used without further purification.

B. Selection of solvents -

Water, methanol and Triethylamine (30:70:2 v/v) was selected as the common solvent for dissolving Apremilast.

C. Selection of stationary phase

On the basis of reversed phase HPLC mode and number of carbon present in molecule (analyte) stationary phase with C18 bonded phase i.e YMC pack C18 (150 mm X 4.6 mm), 5μ m was selected.

D. Selection of Mobile Phase:

The selection of mobile phase was done after assessing the solubility of drug in different solvent as well on the basis of literature survey and finally mobile phase was selected for is the mixture of Water, methanol and Triethylamine in the ratio 30.70:2 v/v,

E. Selection of Detector and Detection wavelength:

UV-visible 2487 detector was selected, as it is reliable and easy to set at the correct wavelength and 234 nm wavelengths was selected as detection wavelength.

F. Optimization of Chromatographic Parameters:

Optimization in HPLC was the process of finding a set of conditions that adequately separate and enable the quantification of the analyte from the endogenous material with acceptable accuracy, precision, sensitivity, specificity, cost, ease and speed.


G. Optimization of mobile phase strength:

The mobile phase chosen after several trials with water, methanol in various proportions which is shown in Table 6.3 finally the mobile phase consisted mixture of Water, methanol and Triethylamine in the ratio 30:70:2 v/v, which resolved the tailing of peak.

The flow rate of 1.0 mL/min was selected as it gave good result, system suitability parameters and reasonable retention time. The retention time of Apremilast was observed 3.3 min at 234 nm wavelength with total run time of 8 min.

H. Optimization of Detection Wavelength:

A fixed concentration of analyte was analyzed at different wavelengths. As per the response of analyte, wavelength of 234 nm was selected. This is the optimum wavelength as it shows maximum absorption at this wavelength.



Stability indicating RP-HPLC development and optimization

I. Praparation of Standard solution:

Accurately weighed 75 mg of Apremilast as working/reference standard was transferred into 100 mL volumetric flask. About 70 mL of diluent added and sonicated to dissolve. The solution was cooled to room temperature and made up to mark with diluent.

Further 4 mL of stock solution of Apremilast was pipette out and transferred to 50 mL volumetric flask and made volume up to mark with Diluent.

J. Linearity studies :

Different levels of standard solution were prepared by diluting out known volumes of intermediate stock solution with the diluent to get the required analyte concentrations. A graph of Concentration (ppm) *vs*.area was plotted and the regression coefficient 'r²', y-intercept and slope of the regression were calculated. weigh accurately about 100 mg of Apremilast standard was taken and transferred to 200 mL volumetric flask, 150 mL of diluent was added, sonicated to dissolve and made up to volume with diluent and mixed.

Level (%)	Concentration		Response	
	(ppm)	1	2	Mean
50	30.13	823983	827014	825498
75	45.80	1222695	1263714	1243205
100	60.01	1681080	1642317	1661699
125	75.03	2088000	2042610	2065305
150	90.12	2462694	2483770	2473232
	0.999			
	16472.5304			
	6763.5826			
	1661700			
%LIMIT O	%LIMIT OF Y-INTERCEPT (± 5 OF WORKING LEVEL)			






Figure A : Calibration curve of Apremilas

K. Preparation of Test Solution

Weighed and Transfered 5 intact tablet of Apremilast into 250 mL volumetric flask. Added about 200 mL of diluent, sonicated for 25 minutes with intermittent shaking cool and dilute up to the mark with diluent and mix, **Allowed** to settle for 15 min. centrifuge this solution at 5000 RPM for 5 min. Further transfered 5 ml of stock solution into 50 ml volumetric flask dilute up to the mark with diluent and mix, **Filtered** through 0.45µ Nylon membrane syringe filter-mdi or equivalent and **injected** (Concentration of Apremilast: About 60 ppm)

L. METHOD VALIDATION-

The developed method was validated as per International Conference on Harmonization (ICH) guidelines with respect to system suitability, Specificity, Linearity, Accuracy, Precision and robustness.

SYSTEM SUITABILITY :

System suitability test is a pharmacopoeial requirement and is used to verify, whether the resolution and reproducibility of the chromatographic system are adequate for analysis to be done.

system suitability test:-

Tailing factor	1.0
Theoretical plates	7402
S. No.	Area
1	1666335
2	1661183
	1660260 1670799
5	1669835
	1666117
Mean % RSD	1665755

Specificity: (Identification, Interference & Peak Purity)

Inject Blank (Diluent), standard solution, impurity Solution, placebo solution and sample solution .The data obtained is summarized in Table


Specificity (Ident<mark>ific</mark>ation and Interference)

Component	Retention time (min)	Tailing factor	Theoretical plates	Purity angle	Purity threshold
Blank			-	-	-
Placebo solution	-	V.	-	-	-
Standard solution	3.350	1.2	7254	0.06	0.86
Sample solution	3.432	1.01	7027	0.07	0.93
	S	Spike solution			
Sample solution	3.351	1.02	7166	0.6	0.84
N-Acetyl Amine	1.96	1.2	3258	0.41	1.45
	2.927	1.0	2704	0.90	1.72

© 2020 JETIR September 2020, Volume 7, Issue 9

www.jetir.org (ISSN-2349-5162)

N-Acetyl Amine	1.98	1.09	3542	0.39	1.56
Des-Acetyl	2.885	1.25	2687	0.82	1.86




Accuracy:- Accuracy (Recovery):

Accuracy was evaluated three levels 50%, 100% and 150% of the working concentration level for Apremilast. As the working concentration level of Apremilast, Each level prepared in triplicates.

© 2020 JETIR September 2020, Volume 7, Issue 9

Level (%)	Theoretical concentration (mcg/mL)	Area	% Recovery	Mean recovery%
50	30.517	856280	100.8	100.6
	30.295	856890	100.9	
	30.298	851653	100.1	
100	60.360	1706792	100.3	100.2
	60.691	1703069	100.2	
	60.366	1699177	100.1	
150	90.283	2529184	99.3	99.3
	90.963	2527490	99.1	
	90.950	2537997	99.5	
		Mean recovery		100
		%RSD		0.6

Precision:



Method Precision: Single injection of blank (Diluent), Standard solution (five replicates) and sample solution (six preparations) was injected on the system.

Method precision

Sample No.	Response	% Assay
1	1635907	99.4
2	1638839	99.8
3	1638810	99.4
4	1636847	99.0
5	1633176	98.6
6	1638572	99.2
Me	ean	99.2
%	RSD	0.4

Intermediate Precision :-Five independent sample preparations were prepared on different day and by different analyst and injected on the HPLC.

Parameter	Method Precision(Analyst- I)	Intermediate Precision(Analyst- II)
HPLC Instrument No.	AD/HPLC-031	AD/HPLC-052
HPLC column No.	C18-134	C18-063
Sample No.	0,	6 Assay
1	99.4	100.1
2	99.8	99.6
3	99.4	99.2
4		
5	98.6	99.5

Table 7.9 Intermediate Precision

Robustness:

This parameter was studied by making small, deliberate changes in the chromatographic conditions and Assay parameters, observing the effect of these changes on the system suitability and results obtained by injecting the standard and sample solutions.

Parameters	Values	Retention Time	Tailing factor	Theoretical plates	%Assay	Absolute difference
Control	As per method		1.1	7125	100.5	-
Flow rate	1.1mL/min	3.4	1.2	7090	100.4	0.1
(± 0.1 mL/min)	0.9mL/min	3.6	1.2	7006	100.3	0.2
Change in	239nm	3.5	1.1	7039	100.5	0.0
Wavelength(± 5 nm)	229 nm	3.5	12	7107	99.1	1.4
Column temperature (±	35°C	3.4	1.2	7092	99.5	1.0
5°C)	25°C	3.6	1.1	7203	99.9	0.6

CONCLUSION

RP-High Performance Liquid Chromatography (HPLC) Method:

HPLC has gained the valuable position in the field of analysis due to ease of performance, specificity, sensitivity and the analysis of sample of complex nature. This technique was employed in the present investigation for estimation of Apremilast tablet formulation. HPLC Water2469 with YMC pack C18 (150 mm X 4.6 mm), 5µm column and UV/PDA detector with empower pro Software was used for the study. The standard and sample solution of Apremilast were prepared in diluent. Different pure solvents of varying polarity in different proportions were tried as mobile phase for development of the chromatogram.

The mobile phase that was found to be most suitable was Water and Methanol, Triethylamine the wavelength 234nm were selected for the evaluation of the chromatogram of Apremilast respectively. The selection of the wavelength was based on the λ max obtained by UV scanning of standard laboratory mixture in water: methanol. This system gave good resolution and optimum retention time with appropriate tailing factor (<2).

After establishing the chromatographic conditions, standard laboratory mixture was prepared and analysed by procedure described under Materials and methods. It gave accurate, reliable results and was extended for estimation of drugs in tablet formulation.

The results from table clearly indicate that the RP-HPLC technique can be successfully applied for the estimation of above-mentioned drugs in their formulation.

SUMMARY

The results of analysis in this method were validated in terms of accuracy, precision, ruggedness, linearity. The method was found to be sensitive, reliable, reproducible, rapid and economic also.

S. No.	0.1 Summary of System Parameters	Acceptance criteria	Resu	lt obtaine	ed
1.0	System suitability The relative standard deviation of six replicate injections	NMT 2.0%		0.3	
	Tailing factor Theoretical plates	NUT 2000		7402	
2.0	Specificity	Results should be comparable	RT of S	tandard: (3.35
2.1	Identification	with respect to the retention time.	RT of Samp	ble	3.432
2.2	Interference	Blank (Diluent), Placebo and known Impurities should not show any peak at the retention time of Apremilast peak	C	omplies	
2.3	Peak purity	Standard and Sample peak should be pure at working concentration level.	Apremilast	Purity angle	Purity Threshold
		Purity angle should be less than	Standard	0.06	0.86
		purity threshold.	Sample	0.07	0.93

Parameters	Acceptance criteria	Re	esult obtained
Linearity and Range Correlation coefficient	NLT 0.990		0.999
Y- intercept	Intercept y <± 2.0% of standard response		1.60
Accuracy (Recovery)			
	Mean and Individual recovery	Level %	% Mean Recovery
			100.6
		100	100.2
	IFTID	150	99.9
Precision	JLIN		
System Precision	System suitability criteria should be fulfilled.		Complies
Method precision	The RSD for % assay of six independent samples preparations: NMT 2.0%.	Š.	ssay 99.2
		% RSI	0.4
	Linearity and Range Correlation coefficient Y- intercept Accuracy (Recovery) Precision System Precision	Linearity and Range Correlation coefficientNLT 0.990Y- interceptIntercept y <± 2.0% of standard responseAccuracy (Recovery)Mean and Individual recovery for 25% to 150% should be in the range of 95.0% - 105.0%.Precision System PrecisionSystem suitability criteria should be fulfilled.Method precisionThe RSD for % assay of six	Linearity and Range Correlation coefficientNLT 0.990Y- interceptIntercept y <± 2.0% of standard responseAccuracy (Recovery)Intercept y <± 2.0% of standard responseAccuracy (Recovery)Mean and Individual recovery for 25% to 150% should be in the range of 95.0% - 105.0%.Precision System PrecisionSystem suitability criteria should be fulfilled.Method precisionThe RSD for % assay of six independent samples

Sr.No	Parameters	Acceptance criteria	Result obtained	
5.3	Intermediate Precision (Ruggedness)	The RSD for % Assay of six independent samples preparation should not be more than 2.0%.		
		The cumulative % RSD for % assay of twelve independent	% Mean Assay	99.4
		samples preparation of two analysts should not more than 2.0%.	% RSD	0.4

© 2020 JETIR September 2020, Volume 7, Issue 9

www.jetir.org (ISSN-2349-5162)

Sr.No	Parameters	Acceptance criteria	Result obtained
6.0	Robustness	System suitability criteria should be fulfilled.	
	Change in Flow rate		
	(± 0.1 mL/min)	The cumulative % RSD for % assay obtained in each modified condition	
	Change in Column temperature $(\pm 5^{\circ}C)$	should not be more than 2.0 when compared to the method precision.	Complies
	Change in Wavelength (±5 nm)		

References:-

- 1. Mendham j., denny r. C., thomas m.; vogel's text book of quantitative chemical analysis; pearson education limited; 6th edition, 2008, 29-39.
- 2. Chatwal g. R., anand s. K.; instrumental methods of chemical analysis; himalaya publishing house, mumbai; 11th edition, 2005, 1.1-1.2, 2.108-2.109, 2.151-2.153.
- **3.** Kasture a. V., wadodkar s. G., mahadikk.r., more h.n.; pharmaceutical analysis instrumental methods, nirali prakashan; 12th edition, 2005; 148-156.
- **4.** Skoog d., leqary j.; principle of instrumental analysis; thomsonasia pvt ltd. Singapore; 54th edition, 2004; 3-8.
- **5.** Skoog d., holler f., timothy a., nieman n.; principles of instrumental analysis; saunders college publications, london; 4th edition, 1992; 1-2, 338-340.
- 6. Settle f.; handbook of instrumental techniques of analytical chemistry. 1st edition, 2004, 19-21, 609-617.
- Corners k. A., textbook of pharmaceutical analysis, a wiley interscience publication, 1st edition, 1967, 475-478
- **8.** Kasture a. V., wadodkar s. G., mahadikk.r., more h.n; textbook of pharmaceutical analysis-ii, nirali prakashan, 13th edition, 2005,1, 47-56
- 9. British pharmacopoeia, 1993, volume ii, 180-190.
- **10.**Kakde r.b., kasturea.v., wadodkar s. G.; indian journal of pharmaceutical sciences, 2002, 64(1), 24-27.
- **11.**Dyade g.k., sharmaa.k.; indian drugs, 2001, 38(2): 75-78.

- **12.**Sethi p.d.; qualitativie analysis of drugs in pharmaceutical formulations, 3rd edition, 1997, 182-184.
- **13.**Swarbrick james.,boylanjames.c.; encyclopedia of pharmaceutical technology, volume i, marcel dekkerinc., new york, 1998, 217 224.
- 14.Lindsay sandy.; hplc by open learning; john wiley and sons, london, 1991, 30-45.
- **15.**Lough w.j., waineri.w.w.; hplc fundamental principles and practices, blackie academic and professional, 1991, 52-67.
- **16.**G. D christian; in: analytical chemistry, 4th edition, john wiley and sons, united kingdom, 1986, 1-6.
- **17.**Meyer veronica r.; practical high performance liquid chromatography, john wiley and sons, london, 2nd edition, 1993, 26, 27, 40, 222, 246, 258.
- **18.**Chatwal g. R., anand s. K.; instrumental method of chemical analysis; himalaya publishing house, 11th edition, 2005, 2.634-2.638
- **19.**Raymond p. W. Scott; liquid chromatography for the analyst, chromatographic science series; marcel dekker, inc., 1991, 1-30.
- 20. Andrea westen; hplc and ce principles and practice; academic press 1997, 1-21.
- **21.**Snyder l.r; high-performance liquid chromatography: advances and perspectives; c. Horvath, ed., academic press, san diego, ca; 1983, 3, 157.
- **22.**Snyder l. R., m. A. Stadalius.; high-performance liquid chromatography: advances and perseptives; c. Horvath, ed., academic press, san diego. ca; 1986, 4, 294-295.
- **23.**Ghulam a. Shabir.; hplc method development and validation for pharmaceutical analysis; pharmaceutical technology europe, march 2004.
- 24.Paul c. Sadek.; troubleshooting hplc systems; john wiley and sons, new york, 2000
- 25.Http://www.waters.com/
- **26.**Sethi p.d.; hplc-quantitative analysis of pharmaceutical formulation; cbs publisher and distributors new delhi; 2001, 11.
- **27.**Ich q2b harmonized tripartite guideline, text on validation of analytical procedures, ifpma, in proceeding of international conference on harmonization, geneva, march 1996.
- **28.**D.a.skoog, f.j. holler, a. Timothy, n.w.nieman, principle of instrumental analysis, saunders college publications, london, 1998.
- **29.**Asean, guideline on stability of drug product, philippines, 2005.

- **30.**S.w.baertschi, p.j. jansen, pharmaceutical stress testing, by taylor&francis group, llc, 2005.
- **31.**S. Klick, stress testing of drug substances and drug products, pharm. Technol. 2005.
- **32.**Ich, stability testing: photostability testing of new drug substances and products q1b, international conference on harmonisation, ifpma, geneva, 1996.
- **33.** Www.drugsbank.com.
- 34. Www. Wikipedia
- **35.**Leon Lachman, H.A. Liberman, J.L. Kanig, "The theory and practice of industrial pharmacy" Third edition, Published by Varghese publishing house, Dadar, Bombay.Page. No: 302,303
- **36.**Gerald K. Shiu, PhD "Dissolution Methodology: Apparatus and conditions" Drug Information Journal, Vol. 30, pp. **1**045–1054, 1996.
- **37.**<u>www.aapspharmac_utica.com/meetings/files/63/thomas.pdf</u> (date- 4 Aug 2016)
- **38.**<u>www.dmsc.moph.gc.th/web/oc/anug/km/dissc/lin.pdf</u> (date- 4 Aug 2016)
- **39.**Bryan Crist, Dan Spisak "Evaluation of Induced Variance of Physical Parameters on the Calibrated USP Dissolution Apparatus 1 and 2" Varian Inc., Analytical Instruments, Cary, NC
- 40.<u>https://www.drug_ank_av/_rugs/DB06677(</u> 4oct.2017)
- **41.**Authorized USP Pending Monograph vesion-1, Correspondence Number-C118798, V.1Authorized January 1,2014 [NEW](USP38NF33_1S)
- **42.**Chaudhari, S.R. and Shirkhedkar, A.A., 2019. Design of experiment avenue for development and validation of RP-HPLC-PDA method for determination of apremilast in bulk and in in-house tablet formulation. Journal of Analytical Science and Technology, 10(1), p.10.
- **43.**Landge, S.B., Dahale, S.B., Jadhav, S.A., Solanki, P.V., Bembalkar, S.R. and Mathad, V.T., 2017. Development and validation of stability indicating rapid RP-LC method for determination of process and degradation related impurities of Apremilast, an anti-inflammatory drug. American Journal of Analytical Chemistry, 8(6), pp.380-394.
- 44.Bhole, R.P., Naksakhare, S.R. and Bonde, C.G., 2019. A Stability Indicating HPTLC Method for Apremilast and Identification of degradation products using MS/MS. Journal of Pharmaceutical Sciences and Research, 11(5), pp.1861-1869.

- **45.**Ravisankar, P., Sulthana, M.S. and Babu, P.S., 2017. Development and validation of stability-indicating UV spectrophotometric method for determination of Apremilast in bulk and pharmaceutical dosage form. Ind J Res Pharm Biotechnol, 5, p.47.
- **46.**Patel, J., Chokshi, P. and Mashru, R., 2020. Validation of Stability Indicating Method and Degradation Kinetic Study of Apremilast. Journal of Drug Delivery and Therapeutics, 10(2), pp.76-85
- **47.**Kulkarni, P. and Deshpande, A., 2020. Analytical Methods for Determination of Apremilast from Bulk, Dosage Form and Biological Fluids: A Critical Review. Critical Reviews in Analytical Chemistry, pp.1-10.
- **48.**Badhe, Pallavi, Smita Aher, and Ravindranath B. Saudagar. "Development and Validation of Spectrophotometric and Chromatographic Method for the Estimation of Apremilast in Bulk and Formulations." Journal of Drug Delivery and Therapeutics 9, no. 6-s (2019): 136-142.
- **49.**Iqbal, Muzaffar, Essam Ezzeldin, Sara TA Al-Rashood, Faisal Imam, and Khalid A. Al-Rashood. "Determination of apremilast in rat plasma by UPLC–MS/MS in ESI-negative mode to avoid adduct ions formation." Bioanalysis 8, no. 14 (2016): 1499-1508.
- 50.Pagar, Kanchan R., Poonam M. Kasar, and Sarika V. Khandbahale. "Analytical Method of Apremilast: A Review." Asian Journal of Pharmaceutical Analysis 10, no. 1 (2020): 44-47.
- **51.**Rao, Tammisetty Mohan, Challa Balasekhara Reddy, and Puttagunta Srinivasa Babu. "LC-MS/MS Determination and Pharmacokinetics Study of Apremilast after Oral Administration in Rabbits." INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH 54, no. 2 (2020): 440-447.
- **52.**Rao, Tammisetty Mohan, Challa Balasekhara Reddy, and Puttagunta Srinivasa Babu. "LC-MS/MS Determination and Pharmacokinetics Study of Apremilast after Oral Administration in Rabbits." INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH 54, no. 2 (2020): 440-447.
- 53.Shakeel, Faiyaz, Nazrul Haq, Fars K. Alanazi, and Ibrahim A. Alsarra. "Solubility and thermodynamics of apremilast in different mono solvents: Determination, correlation and molecular interactions." International Journal of Pharmaceutics 523, no. 1 (2017): 410-417.

- 54.Salode, Vikrant, and M. D. Game. "Development and Validation of Stability Indicating Method for Riociguat with Forced Degradation Studies Using LC-MS." International Journal of Pharmaceutical Sciences and Nanotechnology 13, no. 2 (2020): 4831-4844.
- **55.**Temigire, P. R., Ghani Sobia, V. K. Muniipalli, S. Warde, R. M. Singh, and S. Nayak. "Development and validation of reverse-phase high performance liquid chromatography method for quantitative estimation of riociguat in tablet dosage form." J Pharmacy Res 12, no. 4 (2017): 461-5.
- **56.**Mashru, Rajashree, Hemangi Parekh, and Parin Chokshi. "Analytical Method Development and Validation for the Estimation of Sugammadex." Journal of Drug Delivery and Therapeutics 10, no. 1 (2020): 52-59.
- 57.Hasumati, Raj. "Ranolazine: A Review on Analytical Method and Its Determination in Synthetic Mixture." Asian Journal of Pharmaceutical Analysis 5, no. 4 (2015): 214-218.
- **58.**Parmar, Prashantkumar K., and Arvind K. Bansal. "Novel nanocrystal-based formulations of apremilast for improved topical delivery." Drug Delivery and Translational Research (2020): 1-18.
- **59.**Liu, Yong, Simon Zhou, Mahmoud Assaf, Jim Nissel, and Maria Palmisano. "Impact of renal impairment on the pharmacokinetics of apremilast and metabolite M12." Clinical Pharmacology in Drug Development 5, no. 6 (2016): 469-479.
- **60.**Shakeel, Faiyaz, Nazrul Haq, Fars K. Alanazi, and Ibrahim A. Alsarra. "Solubility and thermodynamic function of apremilast in different (Transcutol+ water) cosolvent mixtures: Measurement, correlation and molecular interactions." Journal of industrial and engineering chemistry 56 (2017): 99-107.